Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
99 results about "Aureobacterium resistens" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Aureobacterium resistens Microbacterium resistens is a bacterium from the genus of Microbacterium which has been isolated from a corneal ulcer in Zürich in Switzerland . [1] [3] [4]
Broad-spectrum antibacterial bacillus amyloliquefaciens strain and application thereof
ActiveCN103173397ASimple cultivation conditionsPromote growthBiocideBacteriaBiotechnologyBacillus amylolyticus
The invention relates to bacillus amyloliquefaciens NCPSJ7 and further relates to an application of the strain in treating plant diseases, diseases before and after harvesting fruits and vegetables as well as in preventing food-borne pathogenic bacteria and putrefying bacteria. The strain is preserved in China Center for Type Culture Collection (CCTCC) on March 22, 2013, wherein the preservation number is CCTCC NO: M2013098 and the strain is named as bacillus amyloliquefaciens NCPSJ7. The thallus and fermentation liquor of the strain disclosed by the invention has the effects of treating plant diseases caused by plant pathogenic fungus including antagonistic peach root rotten disease, fusarium wilt of cucumber, botrytis cinerea, jujube anthracnose, pear black spot, pear blue mould, apple brown rot, apple altermaria leaf spot, watermelon fusarium wilt and the like, as well as diseases after harvesting fruits and vegetables and food-borne pathogenic bacteria and putrefying bacteria including antagonistic staphylococcus aureus, salmonella paratyphi A, vibrio parahaemolyticus, yeast and the like; moreover, the bacillus amyloliquefaciens is broad in spectrum and antibacterial and great in potential in developing novel, efficient and natural biological control and biological preservative and fresh-keeping preparation.
Owner:INST OF AGRO FOOD SCI & TECH SHANDONG ACAD OF AGRI SCI
Fabric having antimicrobial odor-eliminating function
InactiveCN102242500AImprove antistatic performanceImprove stain resistanceFibre treatmentFiberStaphylococcus aureus
The invention discloses a fabric having an antimicrobial odor-eliminating function. An odor-eliminating agent composition and an organic antimicrobial agent are subjected to the padding or coating process, thereby acquiring the fabric. After being subjected to an antimicrobial odor-eliminating process, the fabric can be used for eliminating various odors and resisting staphylococcus aureus. Besides, the process is suitable for various fibers and the fabric after being processed feels good.
Owner:TORAY FIBER RES INST(CHINA) CO LTD
Rhodotorula mucilaginosa and fermentation culture substance and application thereof
ActiveCN106010990AAnti-Staphylococcus aureusResistant to gastric acidAntibacterial agentsFungiAquatic animalStaphylococcus aureus
The invention discloses rhodotorula mucilaginosa and a fermentation culture substance and application thereof. The rhodotorula mucilaginosa is rhodotorula mucilaginosa TZR<2014>, and the preservation number is CCTCC NO:M2015574. Liquid state fermentation is conducted on the rhodotorula mucilaginosa by means of the fermentation culture medium, the biomass of fermentation liquor is 18 g / L, and the yield of carotenoid is 36 mg / L. The rhodotorula mucilaginosa has the effects of resisting staphylococcus aureus, gastric acid and cholate, and a solid fermentation substance of the rhodotorula mucilaginosa further contains pyruvic acid which has the functions of accelerating fat consumption, increasing the muscle yield, phagocytosing free radicals in bodies and inhibiting generation of the free radicals. Therefore, the rhodotorula mucilaginosa can be used for feed additives of livestock, poultry and aquatic animals and has a wide application prospect.
Owner:SOUTHWEST UNIVERSITY
Antibacterial soap and preparation method thereof
InactiveCN102329703AEfficient removalEfficient killingAlkali/ammonium soap compositionsEscherichia coliStaphylococcus aureus
The invention discloses antibacterial soap which is characterized by comprising the following raw material components: 5-15% of coconut oil, 10-20% of palm oil, 3-10% of olive oil, 15-30% of beef tallow, 5-15% of sodium hydroxide, 2-8% of liquorice water extract, 1-3% of sodium dodecyl benzene sulfonate and 3-8% of titanium dioxide. The antibacterial soap obtained in the invention can be directlyapplied to the skin to effectively eliminate and kill bacteria on the skin and can resist staphylococcus aureus, Pseudomonas aeruginosa, escherichia coli and Candida albicans simultaneously.
Owner:NINGXIA MEDICAL UNIV
3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin and application thereof in preparation of medicine for resisting multi-drug resistant bacteria
ActiveCN103333148AHas antibacterial application valueLow inhibitory concentrationAntibacterial agentsOrganic chemistryChemical structureCrystal structure
The invention discloses a novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin with a strong antibacterial effect which is optimized by transforming the structure of bishydroxycoumarin compounds, and provides a preparation method thereof, wherein the chemical structure and crystal structure are obtained. The novel compound 3,3'-(3,4-dichlorobenzylidene)-bis-4-hydroxycoumarin has an antibacterial application value in preparation of a medicine resisting staphylococcus aureus (ATCC29213), methicillin-resistant staphylococcus aureus (MRSA, XJ7502), USA300 (LAC) and vancomycin-resistant staphylococcus aureus (Mu20ATCC700699).
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Application of perylene tetracarboxylic dianhydride amidation compound in anti-staphylococcus aureus
InactiveCN110156781AEasy to makeGood water solubilityAntibacterial agentsOrganic chemistryBacteroidesStaphylococcus cohnii
The invention provides an application of a perylene tetracarboxylic dianhydride amidation compound in anti-staphylococcus aureus. The compound is simple to prepare, a perylene tetracarboxylic dianhydride compound and N,N-dimethylethylenediamine are used as raw materials, multiple steps are carried out, the compound can inhibit the growth of staphylococcus aureus, and the bacteriostasis circle of the compound is up to about 10 mm measured by the K-B method. The compound is subjected to 2-fold gradient dilution, and the measured minimum inhibitory concentration (MIC) against staphylococcus aureus is up to 6.25 mg / mL. The growth curve inhibition test shows that when a growth curve of the bacteria in the non-drug treatment group enters the logarithmic phase, a growth curve of the bacteria in the compound treatment group is still in the lag phase, and indicates that the compound can inhibit the division of staphylococcus aureus. The discovered compound in the future can be used for the control of staphylococcus aureus infection, can also be applied in the preparation of antibacterial biomaterials, and has certain application value.
Owner:HENAN UNIVERSITY
Bovine-derived anti-staphylococcus aureus genetic engineering single-chain antibody, preparation method and application thereof
ActiveCN104926941AHas antibacterial activity in vitroCombined application effect is goodAntibacterial agentsBacteriaStaphylococcus cohniiSingle-Chain Antibodies
The invention belongs to the technical field of genetic engineering and particularly relates to a bovine-derived anti-staphylococcus aureus genetic engineering single-chain antibody, a preparation method and application thereof. The single-chain antibody comprises a bovine antibody light-chain variable region VL, an intermediate junction peptide Linker and a bovine antibody heavy-chain variable regional VH, the connecting sequence thereof is VL-Linker-VH. The amino acid sequence of the bovine antibody light-chain variable region VL is shown as SEQ ID No: 1-8. The amino acid sequence of the bovine antibody heavy-chain variable region VH is shown as SEQ ID No: 9-16. The screened single-chain antibody (scFv) of positive clone is jointly applied to in-vitro and in-vivo inhibition staphylococcus aureus test and achieves ideal antibacterial effect. The single-chain antibody is used for preparing drugs for preventing and curing staphylococcus aureus bovine mastitis.
Owner:安替奔达(宁夏)生物科技有限责任公司
Preparation method of antimicrobial bacterial cellulose material
InactiveCN105860121AGuaranteed long-term effectGuaranteed stabilityPharmaceutical non-active ingredientsAbsorbent padsFiberCell adhesion
The invention relates to a preparation method of an antimicrobial bacterial cellulose material. The method comprises the following steps: adding an organosilicon quaternary ammonium salt into a solvent to obtain an organosilicon quaternary ammonium salt solution; and adding the organosilicon quaternary ammonium salt solution into a bacterial cellulose hydrogel, regulating the pH value to 2.0-7.0, carrying out stirring or oscillating reaction at 5-95 DEG C for 24-72 hours, and cleaning. The method is simple to operate and mild in conditions; and the grafting reaction occurs on the fiber surface, so that the grafting ratio is high. The graft-modified bacterial cellulose material has the advantages of bacterial resistance, protein adsorptivity, cell adhesion promotion characteristic, and specific pH responsivity and temperature responsivity. The antimicrobial bacterial cellulose material has excellent resistance to Staphylococcus aureus and other bacteria, is beneficial to adhesion and growth of the cells in the material, and enhances the application potential of the bacterial cellulose material in the fields of antimicrobial wound dressings, intelligent responsive drug-slow-release carriers, tissue engineering stent biomedicine and the like.
Owner:DONGHUA UNIV
Antibacterial peptide
InactiveCN103641901ABroad spectrum antibacterialAvoid Hemolytic Strong WeaknessesAntibody mimetics/scaffoldsDepsipeptidesBiotechnologyCrystallography
The invention belongs to the technical field of drugs produced by gene engineering in the biotechnological pharmacy industry and in particular relates to an antibacterial peptide. A primary structure of the antibacterial peptide is CLPLLISWIKRKRQQ-AGP-GSKKPVPIIYCNRRTGKCQRM. The newly designed antibacterial peptide simultaneously has the advantages of thanatin and melittin, not only has wide antibacterial spectrum but also can resist staphylococcus aureus and simultaneously avoids the disadvantage that melittin has strong hemolysis.
Owner:HUZHOU TEACHERS COLLEGE
Bovine derived anti-staphylococcus aureus fusion antibody scFv-Fc and preparation method thereof
InactiveCN109021109AGrowth inhibitionHas antibacterial activity in vitroAntibacterial agentsHybrid immunoglobulinsAntigenPhagocyte
The invention discloses a bovine derived anti-staphylococcus aureus fusion antibody scFv-Fc and a preparation method thereof. The fusion antibody scFv-Fc at least has a light chain variable region ofthe amino acid sequence shown as SEQ ID No:1, a heavy chain variable region of the amino acid sequence shown as SEQ ID No:2, an intermediate connecting peptide between the light chain variable regionand the heavy chain variable region, and a Fc fragment of the amino acid sequence shown as SEQ ID No:3. The ELISA result shows that the fusion antibody can be specifically bound to a staphylococcus aureus antigen; in in-vitro bacteriostatic test, the fusion antibody can completely inhibit the growth of staphylococcus aureus within 24h; moreover, the fusion antibody can mediate dairy cow peripheralblood phagocytes in terms of playing the role of conditioning phagocytosis. The fusion antibody can be used in related reagents or drugs for diagnosis, prevention and treatment of staphylococcus aureus cow mastitis.
Owner:SHANGHAI JIAO TONG UNIV
Antibody against staphylococcal enterotoxin B and application thereof
ActiveCN110498854AAntibacterial agentsImmunoglobulins against bacteriaStaphylococcus cohniiStaphylococcus enterotoxin B
The invention discloses an antibody against staphylococcal enterotoxin B and application thereof. The heavy chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 5, SEQ ID No. 6 and SEQ ID No. 7, or is composed of CDR variants with equivalent functions; and light chain of the antibody against staphylococcal enterotoxin B has variable regions CDR1, CDR2 and CDR3 of which the amino acid sequences are shown in SEQ ID NO. 9, SEQ ID No. 10 and SEQ ID No. 11, or is composed of CDR variants with equivalent functions. The antibody against staphylococcal enterotoxin B is capable of specifically binding with staphylococcal enterotoxin B or free enterotoxin B; and thus, the antibody can be used fortreating, preventing and diagnosing staphylococcus aureus infection. Therefore, the antibody against staphylococcal enterotoxin B will be an important research direction in the fields of "non-antibiotic" treatment of methicillin-resistant staphylococcus aureus infection and drug resistance development control.
Owner:ARMY MEDICAL UNIV
Bovine-derived anti-staphylococcus aureus single-chain antibody, preparation method and application thereof
InactiveCN102863528AIn vitroCtiveAntibacterial agentsBacteriaSingle-Chain AntibodiesStaphylococcus cohnii
The invention relates to a bovine-derived anti-staphylococcus aureus single-chain antibody. The antibody at least comprises a light chain variable region of an amino acid sequence which is represented in SEQ ID No.1, a heavy chain variable region of an amino acid sequence which is represented in SEQ ID No.2 and an intermediate connecting peptide which is located between the light chain variable region and the heavy chain variable region. The single-chain antibody can be specifically bound with staphylococcus aureus, has certain external neutralization activity and has good application prospects when used in related reagents or drugs for diagnosing, preventing and treating staphylococcus aureus bovine mastitis.
Owner:SHANGHAI JIAO TONG UNIV
Benzopyran compound and application thereof
ActiveCN107216305AEnhanced inhibitory effectAntibacterial agentsOrganic chemistryBenzopyranChemical compound
The invention relates to a benzopyran compound and application thereof. The benzopyran compound has a structure formula shown in a formula I. The application is the application of the compound in preparing a biological membrane medicine for resisting the staphylococcus aureus. The formula I is shown in the description, wherein R is 3-F, 4-F, 3,5-2F, 3,4,5-3F, 4-C1, 3,4-2C1, 3-Br, and 4-Br.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Derivatives of naftifine hydrochloride as well as preparation method and application thereof
ActiveCN104055756ASimple processAntibacterial agentsOrganic active ingredientsVirulent characteristicsAnti bacterial
The invention discloses derivatives of naftifine hydrochloride as well as a preparation method and application thereof. The derivatives of naftifine hydrochloride are as shown in the formula I. By inhibiting expression and / or function of key catalyzing enzyme CrtN in a golden yellow pigment synthesis pathway and powerfully inhibiting synthesis of golden yellow pigment, virulence of bacteria can be lowered. The key catalyzing enzyme CrtN in the golden yellow pigment synthesis pathway can be taken as a drug acting target; and compounds capable of inhibiting expression and / or function of key catalyzing enzyme CrtN can be used for preparing anti-bacterial drug. The naftifine hydrochloride and the derivatives thereof can be used as inhibitors for catalyzing enzyme CrtN to powerfully inhibit synthesis of the golden yellow pigment, so that the virulence of staphylococcus aureus can be lowered, and therefore, the derivatives can be used for preparing the anti-bacterial drug, especially drug for resisting staphylococcus aureus infection.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
Staphylococcal enterotoxin A chemiluminiscence enzyme-linked immunoassay detection kit
InactiveCN102928599AStrong specificityHigh sensitivityChemiluminescene/bioluminescenceMonoclonal antibodyStaphylococcus aureus enterotoxin
The invention discloses a staphylococcus aureus enterotoxin A chemiluminiscence enzyme-linked immunoassay detection kit. The kit contains a monoclonal antibody resisting staphylococcus aureus enterotoxin A, horseradish peroxidase marked detection antibody solution resisting staphylococcus aureus enterotoxin A, staphylococcus aureus enterotoxin A serial standard solution, wrapping solution, washing solution, closing solution, chemiluminiscence solution and a chemiluminiscence enzyme-linked plate. The staphylococcus aureus enterotoxin A chemiluminiscence enzyme-linked immunoassay detection kit has the advantages of being strong in specificity, high in sensitivity and good in repeatability and is suitable for monitoring diseases and detecting staphylococcus aureus enterotoxin A in food and blood in rapid quantitative mode.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Antimicrobial diapers and wet wipes
InactiveUS7105177B1Cheap methodEasily biodegradableCosmetic preparationsBiocideAcid derivativeWet wipe
Diapers and wet wipes for cleansing of infants are made anti-bacterial by the inclusion therein of hop acid derivatives, specifically tetrahydroiso-alpha acid and hexahydro-beta acid. These compounds are effective to inhibit the growth of gram-positive bacteria, and specifically chosen to combat Staphylococcus aureus, a primary factor in toxic shock syndrome in infants.
Owner:MILLERCOORS
Anti-Staphylococcus aureus alpha hemolysin monoclonal antibody and applications thereof
ActiveCN109384844AInhibit hemolytic activityHigh affinityAntibacterial agentsImmunoglobulins against bacteriaPhage antibodiesStaphylococcus cohnii
The invention discloses an anti-Staphylococcus aureus alpha hemolysin monoclonal antibody and applications thereof, wherein the monoclonal antibody comprises a heavy chain and a light chain, the aminoacid sequence of the variable region of the heavy chain is represented by the sequence 2 in the sequence listing, and the amino acid sequence of the variable region of the light chain is representedby the sequence 4 in the sequence listing. According to the present invention, the full human source anti-alpha hemolysin monoclonal antibody is rapidly screened from the phage antibody library by using the alpha hemolysin as the target antigen; and the obtained monoclonal antibody is the completely-new antibody, has high affinity, can highly inhibit the hemolytic activity of alpha-hemolysin, canimprove the survival rate of mice infected with Staphylococcus aureus, and further has important application value in the prevention and control of Staphylococcus aureus.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Bacteria detection kit
The invention discloses a double-labeled gold nanorod probe, which is obtained by adding a urease solution into a suspension of the gold nanorods dropwise for mixing and swirling, adding anti-staphylococcus aureus antibody solution dropwise for mixing and swirling, and finally centrifuging and supernatant abandoning. The double-labeled probe converts the quantity signal of SA into a pH change of the solution by the catalytic action of urease and the specific recognition of IgY. A detection kit for staphylococcus aureus is provided at the same time, comprising the double-labeled gold nanorod probe, non-specific magnetic beads, saturated urea and phenolphthalein test paper, wherein the double-labeled gold nanorod probe is labeled with urease and anti-staphylococcus aureus antibody; the result is rapidly detected by phenolphthalein test paper from white to magenta. The invention has the advantages that the kit is easy to operate; the test result can be interpreted by naked eyes under natural light without any instrument; comparison with a standard color chart can be carried out to obtain semi-quantitative detection results; and the detection is fast and can be completed in 20 minutes.
Owner:JILIN UNIV
Antibody for resisting staphylococcus aureus toxin and applications thereof
ActiveCN109705213AAchieve infectionAntibacterial agentsImmunoglobulins against bacteriaStaphylococcus cohniiHeavy chain
The invention discloses an antibody for resisting staphylococcus aureus toxin and applications thereof, and relates to the technical field of antibodies. According to the antibody or a fragment thereof which is specifically combined with staphylococcus aureus toxin, the antibody or the fragment thereof can be specifically combined with a staphylococcus aureus gamma-hemolysin H1gB component, and can generate a cross reaction with other hemolysin components of the the hemolysin. The antibody comprises a variable region of heavy chain (VH) and a variable region of light chain (VL), wherein the variable region of heavy chain (VH) comprises the following CDR combination: VH-CDR1, VH-CDR2 and VH-CDR3, and the variable region of light chain (VL) comprises the following CDR combination: VL-CDR1, VL-CDR2 and VL-CDR3. The present invention can exert the effect of neutralizing, at least including neutralizing H1gB two-component toxin, thereby achieving the treatment of staphylococcus aureus infection alone or in combination with anti-staphylococcus aureus chemical drugs.
Owner:SHANGHAI CHANGZHENG HOSPITAL
A bovine-derived anti-staphylococcus aureus eukaryotic expression single chain antibody, a preparing method thereof and uses of the antibody
InactiveCN106397585AAntibacterial agentsImmunoglobulins against bacteriaInflammatory factorsStaphylococcus cohnii
A bovine-derived anti-staphylococcus aureus eukaryotic expression single chain antibody, a preparing method thereof and uses of the antibody are disclosed. The eukaryotic expression single chain antibody at least comprises a bovine-derived single chain antibody segment VL-Linker-VH formed by connecting a bovine antibody light chain variable region VL having an amino acid sequence shown as SEQ ID No.1, a bovine antibody heavy chain variable region VH having an amino acid sequence shown as SEQ ID No.2, and a middle connecting peptide Linker according to a VL-Linker-VH order. After a coding gene of the segment is inserted into an eukaryotic expression vector to construct a single chain antibody eukaryotic expression plasmid pcDNA3.1-scFv, the pcDNA3.1-scFv is directly injected to a mouse mammary tissue, and therefore contents (P<0.05) of cell factors IFN-gamma and IL-4 can be significantly increased, the content of an inflammatory factor TNF-alpha (P<0.05) can be reduced, relative integrity of the mammary structure can be maintained, infiltration of inflammatory cells is reduced and a mouse is provided with certain protection.
Owner:SHANGHAI JIAO TONG UNIV
Staphylococcus aureus ITC (Inverse Transition Cycling) fusion protein as well as preparation method and application thereof
ActiveCN103570835AGood immune effectImprove immunityAntibacterial agentsAntibody medical ingredientsAntigenStaphylococcus cohnii
The invention discloses a staphylococcus aureus ITC (Inverse Transition Cycling) fusion protein which is a protein formed by fusing IsdB immunodominance fragments (IsdBid) and Trap as well as a ClfA immunodominance fragment N3 area (ClfAN3); an amino acid sequence of the fusion protein is as shown in SEQ ID NO.2. The invention further provides a coding gene, a preparation method and application of the fusion protein in preparing a vaccine for preventing staphylococcus aureus infection. The ITC fusion protein disclosed by the invention contains various antigens, and therefore, immune effect is good, protective effect of preventing staphylococcus aureus infection is improved; compared with the immune result of any of ClfA, IsdB and TraP, the ITC fusion protein immune effect is better than that of single protein; moreover, the ITC contains Trap with smaller molecular weight and has an immunodominance fragment with two antigens, so that peptide chain length is not lengthy, and therefore, the fusion protein is beneficial to in-vitro expression and has important value in developing and applying a novel vaccine for preventing staphylococcus aureus.
Owner:HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
Chemiluminescent enzyme-linked immunoassay detection kit for staphylococcal enterotoxin C
ActiveCN102944678AStrong specificityHigh sensitivityChemiluminescene/bioluminescenceMonoclonal antibodyHorseradish peroxidase
The invention discloses a chemiluminescent enzyme-linked immunoassay detection kit for staphylococcal enterotoxin C. The contents of the kit comprise a staphylococcal enterotoxin C-resistant monoclonal antibody, a horseradish peroxidase-marked staphylococcal enterotoxin C-resistant detection antibody solution, a staphylococcal enterotoxin C series standard solution, a coating solution, a sealing solution, a cleaning solution, a chemiluminescent solution and a chemiluminescent enzyme-linked plate. The kit has the characteristics of high specificity, sensitivity and repeatability, and is suitable for monitoring diseases and quickly and quantitatively detecting staphylococcal enterotoxin C in foods and blood.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
InactiveUS20180021450A1Antibacterial agentsOrganic active ingredientsStaphylococcus aureus bacteriaAureobacterium resistens
Owner:GENENTECH INC
Preparation and application of anti-staphylococcus aureus polyclonal antibody
InactiveCN104211804AAntibacterial agentsImmunoglobulins against bacteriaNew Zealand white rabbitPolyclonal antibodies
The invention discloses a novel anti-staphylococcus aureus polyclonal antibody for treating staphylococcus aureus infection. The antibody is obtained by immunizing a New Zealand white rabbit with staphylococcus aureus MntC protein as a major immunizing antigen. The novel anti-staphylococcus aureus polyclonal antibody has an immune regulation effect and is capable of promoting the phagocytosis of the organism to the staphylococcus aureus so as to achieve the effect of treating the staphylococcus aureus infection.
Owner:钱泓
Fully human anti-staphylococcus aureus alpha-hemolysin recombinant antibody
ActiveCN110437334AStrong penetrating powerSmall molecular weightHybrid immunoglobulinsImmunoglobulins against bacteriaSingle-Chain AntibodiesStaphylococcus cohnii
The invention discloses an anti-staphylococcus aureus alpha-hemolysin single-chain antibody scFv2 or scFv46, further discloses an anti-staphylococcus aureus alpha-hemolysin recombinant antibody scFv2-Fc or scFv46-Fc containing the scFv2 or scFv46 and a human antibody constant region Fc segment amino acid sequence, and further discloses a universal expression vector sp-Fc / pcDNA3.1 of the fully human anti-staphylococcus aureus alpha-hemolysin recombinant antibody. The nucleic acid sequence of an encoding gene of the universal expression vector is shown in SEQ ID No:13. The invention further discloses a eukaryotic expression vector of the fully human anti-staphylococcus aureus alpha-hemolysin recombinant antibody. The eukaryotic expression vector is obtained by inserting the single-chain antibody into the sp-Fc / pcDNA3.1. The invention further discloses a recombinant expression vector sp-scFv2-Fc / pMH3 or sp-scFv46-Fc / pMH3.
Owner:SOUTHWEST MEDICAL UNIVERISTY
Preparation and application of anti-Staphylococcus aureus eLtaS protein monoclonal neutralizing antibody E4-2
ActiveCN103951749AAntibacterial agentsImmunoglobulins against bacteriaStaphylococcus cohniiNeutralizing antibody
The invention discloses an anti-Staphylococcus aureus eLtaS protein monoclonal neutralizing antibody E4-2, belonging to the technical field of preparation of antibodies for immunization. An antibody light / heavy chain variable region gene is cloned from the prepared eLtaS neutralizing monoclonal antibody E4-2, and can code correct mouse antibody variable regions. The light / heavy chain variable region gene based on the monoclonal antibody can be used for constructing and expressing multiple micromolecule gene engineering antibodies; and the polypeptide or protein coded on the basis of the gene can crosslink multiple biological activity molecules for preparing anti-Staphylococcus aureus infection drugs, and has wide application prospects.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Staphylococcus aureus capsular polysaccharide and protein conjugate and preparation method and application thereof
InactiveCN101914144AEnhance immune responseStrong adjuvant functionAntibacterial agentsDepsipeptidesStaphylococcus cohniiSpecific immunity
The invention discloses a staphylococcus aureus capsular polysaccharide and protein conjugate and preparation method and application thereof. Salmonella typhimurium flagellin or polylysine salmonella typhimurium flagellin is taken as a carrier, and staphylococcus aureus capsular polysaccharide is subject to chemical modification, and then chemical coupling is carried out on the staphylococcus aureus capsular polysaccharide and the carrier protein. As the salmonella typhimurium flagellin and polylysine salmonella typhimurium flagellin have immunologic adjuvant function, the new formed conjugate can cause staphylococcus aureus capsular polysaccharide with extremely low immunogenicity to have higher immunogenicity, and the carrier protein plays the immunologic adjuvant function when in inoculation, so that specific immune response of immune animal to the staphylococcus aureus capsular polysaccharide is enhanced. The invention has wide application in preparation of vaccine resisting staphylococcus aureus infection.
Owner:ZHEJIANG UNIV
An extract for regulating female vaginal microecology
The invention discloses a traditional Chinese medicine composition for adjusting female vaginal microecology. The traditional Chinese medicine composition comprises: be weight, 1 to 2 parts of licorice, 1 to 2 parts of clove, 1 to 2 parts of common cnidium fruit, 1 to 2 parts of pomegranate rind, 1 to 2 parts of Chinese gall, 1 to 2 parts of giant knotweed, 1 to 2 parts of Chinese magnoliavine fruit, 1 to 2 parts of anemone root, 1 to 2 parts of coptis root, 1 to 2 parts of amur corktree bark, 1 to 2 parts of aucklandia root and 1 to 2 parts of raw stemona root. The traditional Chinese medicine composition can be utilized directly for a female vagina to remove effectively pathogenic bacteria in the female vagina. The traditional Chinese medicine composition can kill staphylococcus aureus,staphylococcus epidermidis, streptococcus faecalis, escherichia coli, bacillus proteus, candida albicans, candida tropicalis, candida krusei and other candidas simultaneously.
Owner:NINGXIA MEDICAL UNIV
Curcuminoid condensed aromatic amine Schiff base derivative, as well as preparation method and application thereof in preparation of antibacterial medicaments
InactiveCN103159644AGood inhibitory effectImprove bioavailabilityAntibacterial agentsOrganic active ingredientsStaphylococcus aureusNitrogen gas
Owner:TANGSHAN NORMAL UNIV
Medicine with resistance to staphylococcus aureus as well as preparation method and application of medicine
InactiveCN106619829AIncreased sensitivityReduce dosageAntibacterial agentsOrganic active ingredientsAntibiotic YStaphylococcus aureus
The invention belongs to the field of biological medicines and particularly relates to a medicine with resistance to staphylococcus aureus as well as a preparation method and application of the medicine. The medicine with resistance to staphylococcus aureus comprises a traditional Chinese medicine composition and antibiotics, wherein the traditional Chinese medicine composition is prepared from flos lonicerae, radix scutellariae and fructus forsythiae according to a weight ratio of 1 to (0.1-1) to (0.5-2); the antibiotics are selected from one of cefradine, levofloxacin and gentamicin. With combination of the traditional Chinese medicine composition and the antibiotics, the sensibility to antibiotics of staphylococcus aureus can be improved; the medicine resistance is difficultly generated when frequently taking the medicine; meanwhile, the dosage of the antibiotics can be effectively reduced; the occurrence of adverse effect of medicinal hematuria can be reduced; the medicine has a good application prospect; the invention further provides application of the medicine with resistance to staphylococcus aureus to preparation of medicines or antibacterial products.
Owner:SOUTH CHINA SEA FISHERIES RES INST CHINESE ACAD OF FISHERY SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com